Erste Asset Management GmbH lifted its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 47.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 739,332 shares of the company's stock after buying an additional 239,332 shares during the quarter. Erste Asset Management GmbH owned about 1.29% of Ginkgo Bioworks worth $6,979,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of DNA. Forbes J M & Co. LLP lifted its stake in shares of Ginkgo Bioworks by 461.4% during the 4th quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock valued at $6,891,000 after buying an additional 576,732 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Ginkgo Bioworks during the 3rd quarter worth approximately $2,282,000. BNP Paribas Financial Markets bought a new stake in Ginkgo Bioworks during the 3rd quarter worth approximately $1,287,000. PDT Partners LLC bought a new stake in Ginkgo Bioworks during the 3rd quarter worth approximately $1,199,000. Finally, Verition Fund Management LLC bought a new stake in Ginkgo Bioworks during the 3rd quarter worth approximately $792,000. 78.63% of the stock is currently owned by hedge funds and other institutional investors.
Ginkgo Bioworks Stock Performance
Ginkgo Bioworks stock traded down $0.50 during midday trading on Tuesday, reaching $7.28. 952,671 shares of the stock were exchanged, compared to its average volume of 1,403,782. The company's fifty day moving average is $10.98 and its 200-day moving average is $9.20. The firm has a market cap of $422.20 million, a PE ratio of -0.56 and a beta of 1.23. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.26 and a 52 week high of $48.00.
About Ginkgo Bioworks
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
